Sancuso

Chemotherapy, Operative Surgery, Nausea + 1 more

Treatment

3 FDA approvals

20 Active Studies for Sancuso

What is Sancuso

Granisetron

The Generic name of this drug

Treatment Summary

Ondansetron is a medication used to prevent nausea and vomiting caused by cancer treatments, such as chemotherapy. It works by blocking serotonin, a chemical that can cause nausea and vomiting.

Kytril

is the brand name

image of different drug pills on a surface

Sancuso Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Kytril

Granisetron

1993

63

Approved as Treatment by the FDA

Granisetron, also known as Kytril, is approved by the FDA for 3 uses such as Nausea and vomiting and Nausea .

Nausea and vomiting

Nausea

Chemotherapy

Effectiveness

How Sancuso Affects Patients

Granisetron is a medication that works by blocking a type of serotonin receptor (5-HT3) found in the nerves, brain, and GI tract. It has no effect on other receptors or other parts of the body, such as the heart or blood pressure. It is related to another drug called ondansetron, which works similarly. Chemotherapy drugs can cause damage to the GI tract and release serotonin, which then stimulates nerve receptors in the brain and leads to nausea and vomiting. Granisetron blocks these serotonin receptors and helps prevent nausea and vomiting.

How Sancuso works in the body

Granisetron stops the vomiting center in your brain from being stimulated. It does this by blocking 5-HT3 receptors, which are found in the brain and in the gastrointestinal tract. Blocking these receptors prevents the sensations that can trigger vomiting.

When to interrupt dosage

The suggested measure of Sancuso is contingent upon the diagnosed circumstance, including Nausea, Radiation Therapy and Operative Surgery. The magnitude of dosage fluctuates, relative to the technique of administration (e.g. Solution - Oral or Injection, solution) delineated in the table underneath.

Condition

Dosage

Administration

Operative Surgery

, 1.0 mg/mL, 0.1 mg/mL, 1.0 mg, 0.31 mg/hour, 4.0 mg/mL, 100.0 mg/mL, 1.12 mg/mL, 0.2 mg/mL

, Intravenous, Injection - Intravenous, Injection, Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, Tablet - Oral, Patch - Transdermal, Transdermal, Patch, Injection, solution, Injection, solution - Intravenous, Solution - Intravenous, Subcutaneous, Injection - Subcutaneous, Solution - Oral, Solution, Liquid, Liquid - Intravenous

Radiation Therapy

, 1.0 mg/mL, 0.1 mg/mL, 1.0 mg, 0.31 mg/hour, 4.0 mg/mL, 100.0 mg/mL, 1.12 mg/mL, 0.2 mg/mL

, Intravenous, Injection - Intravenous, Injection, Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, Tablet - Oral, Patch - Transdermal, Transdermal, Patch, Injection, solution, Injection, solution - Intravenous, Solution - Intravenous, Subcutaneous, Injection - Subcutaneous, Solution - Oral, Solution, Liquid, Liquid - Intravenous

Chemotherapy

, 1.0 mg/mL, 0.1 mg/mL, 1.0 mg, 0.31 mg/hour, 4.0 mg/mL, 100.0 mg/mL, 1.12 mg/mL, 0.2 mg/mL

, Intravenous, Injection - Intravenous, Injection, Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, Tablet - Oral, Patch - Transdermal, Transdermal, Patch, Injection, solution, Injection, solution - Intravenous, Solution - Intravenous, Subcutaneous, Injection - Subcutaneous, Solution - Oral, Solution, Liquid, Liquid - Intravenous

Nausea

, 1.0 mg/mL, 0.1 mg/mL, 1.0 mg, 0.31 mg/hour, 4.0 mg/mL, 100.0 mg/mL, 1.12 mg/mL, 0.2 mg/mL

, Intravenous, Injection - Intravenous, Injection, Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, Tablet - Oral, Patch - Transdermal, Transdermal, Patch, Injection, solution, Injection, solution - Intravenous, Solution - Intravenous, Subcutaneous, Injection - Subcutaneous, Solution - Oral, Solution, Liquid, Liquid - Intravenous

Warnings

There are 20 known major drug interactions with Sancuso.

Common Sancuso Drug Interactions

Drug Name

Risk Level

Description

Anagrelide

Major

The risk or severity of QTc prolongation can be increased when Granisetron is combined with Anagrelide.

Apomorphine

Major

The risk or severity of hypotension can be increased when Granisetron is combined with Apomorphine.

Arsenic trioxide

Major

The risk or severity of QTc prolongation can be increased when Granisetron is combined with Arsenic trioxide.

Artemether

Major

The risk or severity of QTc prolongation can be increased when Granisetron is combined with Artemether.

Asenapine

Major

The risk or severity of QTc prolongation can be increased when Granisetron is combined with Asenapine.

Sancuso Toxicity & Overdose Risk

The lethal dose of this drug for a rat is higher than 2000mg/kg when given orally.

image of a doctor in a lab doing drug, clinical research

Sancuso Novel Uses: Which Conditions Have a Clinical Trial Featuring Sancuso?

85 ongoing clinical trials are assessing the potential of Sancuso to alleviate Nausea, enhance Operative Surgery outcomes and reduce the side effects of Radiation Therapy.

Condition

Clinical Trials

Trial Phases

Operative Surgery

68 Actively Recruiting

Phase 3, Not Applicable, Phase 4, Phase 1, Phase 2

Radiation Therapy

8 Actively Recruiting

Not Applicable, Phase 1, Phase 3, Phase 2

Nausea

0 Actively Recruiting

Chemotherapy

5 Actively Recruiting

Phase 1, Phase 3, Not Applicable, Phase 2

Sancuso Reviews: What are patients saying about Sancuso?

5

Patient Review

12/8/2012

Sancuso for Prevent Nausea and Vomiting from Cancer Chemotherapy

The Sancuso patch was an absolute godsend. My partner has inoperable stage 3b lung cancer and was dreading her next round of chemotherapy. But we decided to try the patch, and it worked like a charm! She had no side effects from the chemo at all—it was like she didn't even have a treatment. I'm nearly in tears thinking about how many treatments/tortures she went through before this patch. It's been a miracle!

3

Patient Review

6/4/2010

Sancuso for Severe Nausea and Vomiting that has Lasted a Long Time

The price is quite high, but it did help me.

2.3

Patient Review

6/28/2014

Sancuso for Prevent Nausea and Vomiting from Cancer Chemotherapy

The patches are pretty effective, but they just don't stay on. I've tried using tape around the edges, but it really doesn't help much.

2.3

Patient Review

9/2/2013

Sancuso for Nausea and Vomiting caused by Cancer Drugs

I'm sorry to say that this product didn't work for me. I had an allergic reaction to the sancuso patch.

1.7

Patient Review

9/27/2022

Sancuso for Prevent Nausea and Vomiting from Cancer Chemotherapy

The patch didn't even last a full day before it came off.

Patient Q&A Section about sancuso

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How does Sancuso patch work?

"This medication is used in order to prevent nausea and vomiting which is caused by cancer drug treatment (chemotherapy). The way it works is by blocking one of the body's natural substances (serotonin) which can cause vomiting."

Answered by AI

What is Sancuso used for?

"Sancuso is a prescription drug that is used to treat the symptoms of nausea and vomiting that are caused by chemotherapy, radiation, and surgery. It may be used alone or with other medications. Sancuso belongs to a class of drugs called antiemetics, which are drugs that block the action of the chemical serotonin."

Answered by AI

How much does Sancuso cost?

"The lowest price for Sancuso is around $624.65, which is 13% lower than the average retail price of $723.92. You can compare prices for different serotonin antagonists to get the best deal."

Answered by AI

How long does Sancuso patch last?

"The transdermal patch should be removed 24 hours after the chemotherapy is completed. It can be worn for up to 7 days, depending on how long the chemotherapy takes."

Answered by AI

Clinical Trials for Sancuso

Image of Nationwide Children's Hospital in Columbus, United States.

Handheld Ultrasound Device for Surgery

1 - 6
All Sexes
Columbus, OH

This a prospective study in pediatric patients undergoing surgery and requiring placement of an intravenous cannula. This will be a novel study to assess whether a handheld compatible cardiac ultrasound device (Lumify) can be used to quickly and reliably verify successful vascular cannulation in pediatric patients using the rapid atrial swirl sign (RASS) technique. As emerging technologies have made hand-held ultrasound devices more versatile, portable, and cheaper, it will be important to prove if they can be as accurate as traditional ultrasound devices for their intended focused point-of-care functions. If the handheld device is deemed efficacious, it will allow the use of a portable hand-held device rather than the more difficult to transport devices (Sonosite).

Waitlist Available
Has No Placebo

Nationwide Children's Hospital

Alok Moharir, MD

Have you considered Sancuso clinical trials?

We made a collection of clinical trials featuring Sancuso, we think they might fit your search criteria.
Go to Trials
Image of University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center in Cleveland, United States.

Music Therapy for Surgery

50 - 80
All Sexes
Cleveland, OH

Participants may take part in this study if they are scheduled to undergo a surgery that meets the following: (1) traditional open surgery via laparotomy, (2) length of surgery \>3 hours, and (3) curative-intent surgical resection of a cancer in the stomach, pancreas, bile ducts, liver, or peritoneal surfaces. The purpose of this study is (1) to evaluate the feasibility of collecting blood samples prior to surgery, post-surgery and pre- music-assisted relaxation and imagery (MARI) intervention, and immediately post-MARI intervention and (2) to identify gene expression changes associated with MARI and explore their relationship with immediate changes in pain intensity. Participants will be in this study for the duration of their hospital admission for surgery.

Waitlist Available
Has No Placebo

University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center

Samuel N Rodgers-Melnick, PhD, MPH

Have you considered Sancuso clinical trials?

We made a collection of clinical trials featuring Sancuso, we think they might fit your search criteria.
Go to Trials
Image of UW Health in Madison, United States.

Automated vs Specialist-Delivered Training for Surgery

18+
All Sexes
Madison, WI

This study evaluates strategies to train surgeons to use Better Conversations, an evidence-based communication framework designed to improve informed consent by helping patients understand the goals of surgery, the downsides of treatment, and what to expect. Better Conversations supports deliberation, patient preparation, and alignment of decisions with patient goals, addressing known shortcomings in traditional informed consent. The purpose of this study is to compare two methods of surgeon training: (1) training delivered by an education specialist using audit and feedback, and (2) training supported by computerized automation that identifies elements of Better Conversations in de-identified transcripts of surgical consultations. The central question is whether the automated training program is non-inferior to the specialist-delivered program. Approximately 60 surgeons from two academic health systems will be randomized to one of these training approaches. Each surgeon will complete a didactic session, have outpatient surgical consultations audio-recorded for feedback, and complete assessment recordings after training. Patients of enrolled surgeons will complete surveys before and after their surgeon's training to evaluate patient-reported communication outcomes. Findings from this study will assess the effectiveness, feasibility, and acceptability of automated training and support the development of a larger pragmatic study to evaluate the broader effects of Better Conversations on patient outcomes.

Waitlist Available
Has No Placebo

UW Health (+1 Sites)

Margaret (Gretchen) L Schwarze, MD, MPP

Image of Nationwide Children's Hospital in Columbus, United States.

TetraGraph for Neuromuscular Blockade

Any Age
All Sexes
Columbus, OH

In most clinical instances, direct laryngoscopy and endotracheal intubation is performed after a set time (generally 60 seconds) following the administration of a neuromuscular (NM) blocking agent, rocuronium. Although the average onset time is 60 seconds, clinical studies show a standard deviation around the mean onset time of 10-20 seconds, meaning that a significant number of patients do not achieve complete NM blockade by 60 seconds. Given the above noted variability, complete NM blockade may not be achieved in 60 seconds in a significant percentage of patients, resulting in more problematic direct laryngoscopy and endotracheal intubation. Various studies have shown a higher incidence of perioperative respiratory events and postoperative concerns (sore throat, vocal cord injury) when NM blockade is not complete prior to endotracheal intubation. This study aims to use the TetraGraph monitor to clearly identify onset times of rocuronium. Additionally, whenever feasible based on the clinical needs of the case, recovery times after the single dose of rocuronium will be recorded.

Waitlist Available
Has No Placebo

Nationwide Children's Hospital

Joseph Tobias, MD

Have you considered Sancuso clinical trials?

We made a collection of clinical trials featuring Sancuso, we think they might fit your search criteria.
Go to Trials